| domain | knowledge-base annotation | ontology suggestions | evidence caveat |
|---|---|---|---|
| Disease scope | **Necrotizing vasculitis** should be modeled primarily as a **pathologic/morphologic vasculitis pattern** characterized by vessel wall necrosis, not a single etiologically uniform disease entity. In current vasculitis nomenclature, it spans several syndromes, especially **ANCA-associated vasculitis (AAV)**, but also other entities such as polyarteritis nodosa/cutaneous arteritis depending on vessel size and context. (pqac-00000000, pqac-00000002, pqac-00000003) | MONDO:0800113 necrotizing vasculitis; MeSH/ICD mapping should be treated cautiously; related disease labels: anti-neutrophil cytoplasmic antibody-associated vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis | MONDO term exists, but literature often uses “necrotizing vasculitis” descriptively/histopathologically rather than as a discrete disease diagnosis. |
| Relationship to AAV | AAV is the best-supported modern clinical framework linked to necrotizing vasculitis: **pauci-immune small-vessel necrotizing inflammation** affecting kidney, lung, skin, ENT, nerves, and other organs. AAV includes GPA, MPA, and EGPA; renal-limited necrotizing crescentic GN is part of the spectrum. (pqac-00000002, pqac-00000005) | Related MONDO labels: anti-neutrophil cytoplasmic antibody-associated vasculitis; granulomatosis with polyangiitis; microscopic polyangiitis; eosinophilic granulomatosis with polyangiitis | Evidence is strongest for AAV, so many annotations below are **subtype-derived** rather than universal for all necrotizing vasculitis. |
| Core pathology | Hallmark lesion: **acute necrotizing inflammation of vessel walls**, often with **few or no immune deposits** in AAV, driven by activated leukocytes causing endothelial injury, fibrinoid necrosis, and downstream scarring/resolution. In kidney, classic lesion is **necrotizing crescentic glomerulonephritis**. (pqac-00000001, pqac-00000002, pqac-00000005) | HPO labels: vasculitis, glomerulonephritis, hematuria, proteinuria; GO labels: neutrophil activation, complement activation, endothelial cell activation | “Pauci-immune” language applies mainly to AAV; immune-complex necrotizing vasculitis exists in other settings. |
| Major phenotypes/organs | Common high-yield manifestations in AAV-linked necrotizing vasculitis include **rapidly progressive glomerulonephritis**, pulmonary disease (nodules, infiltrates, alveolar hemorrhage), ENT disease (sinonasal inflammation/crusting), skin lesions (purpura/ulcers), peripheral neuropathy, constitutional symptoms, and hypertension with renal involvement. (pqac-00000004, pqac-00000005) | UBERON labels: kidney, glomerulus, lung, upper respiratory tract, skin, peripheral nerve, blood vessel; HPO labels: hematuria, proteinuria, pulmonary hemorrhage, sinusitis, hearing impairment, purpura, neuropathy | Organ spectrum differs by subtype: GPA is more granulomatous/ENT-pulmonary; MPA is more renal-pulmonary; EGPA adds eosinophilic/asthmatic features. |
| Key autoantigens / causal immune targets | Core autoantigen system in AAV: **MPO** and **PRTN3/PR3**. ANCA binding to surface-exposed MPO/PR3 on primed neutrophils drives neutrophil activation and vascular injury. (pqac-00000002, pqac-00000005) | Gene labels: **MPO**, **PRTN3**; protein labels: myeloperoxidase, proteinase 3 | Strongest mechanistic evidence for MPO-ANCA pathogenicity; PR3-ANCA pathogenicity is supported but historically less direct in animal transfer models. |
| Genetic susceptibility | Susceptibility is polygenic and subtype/serotype-biased; repeatedly implicated loci/genes include **HLA-DP** region, **SERPINA1**, and **PRTN3**, with additional immune loci reported in AAV precision-medicine/genetic studies. (pqac-00000006) | Gene labels: **HLA-DP** (region label; avoid exact ID if uncertain), **SERPINA1**, **PRTN3** | These are **risk-associated loci**, not monogenic causes of “necrotizing vasculitis” as an umbrella term. |
| Drug/therapeutic target genes | Clinically actionable targets strongly associated with AAV/necrotizing vasculitis include **MS4A1 (CD20)** for rituximab, **C5AR1** for avacopan, and **IL5** for mepolizumab in EGPA; Open Targets also links these to MONDO:0800113. (pqac-00000000) | **MS4A1/CD20**, **C5AR1**, **IL5** | Target-disease links are strongest for specific AAV subtypes and approved therapies, especially GPA/MPA for CD20 and C5aR1, EGPA for IL-5. |
| Immune cells | Central effector cell: **neutrophil**. Additional important cells: **B cells/plasmablasts** (ANCA production), **T cells** (pathogenic helper/cytotoxic programs), **monocytes/macrophages**, and **endothelial cells** as injury targets. (pqac-00000001, pqac-00000002) | CL labels: neutrophil, B cell, T cell, monocyte, macrophage, endothelial cell | Relative contribution varies by tissue and subtype; eosinophils are particularly relevant in EGPA though not universal. |
| Renal tissue/cell programs | In ANCA glomerulonephritis, injury involves **glomerular endothelial cells**, infiltrating innate/adaptive immune cells, and crescent-forming epithelial compartments; recent spatial/single-cell work identified inflammatory niches and pathogenic T-cell signatures in kidney tissue. (pqac-00000004) | UBERON labels: kidney, renal glomerulus; CL labels: endothelial cell, CD4-positive T cell, CD8-positive T cell; GO labels: cell adhesion, cytokine-mediated signaling | Advanced omics data are currently **renal AAV-specific**, not broad evidence for every necrotizing vasculitis context. |
| Pathway mechanisms | Dominant mechanistic chain in AAV-linked necrotizing vasculitis: priming factors/infection-inflammatory milieu → surface MPO/PR3 exposure on neutrophils → ANCA binding/FcγR signaling → **alternative complement amplification with C5a** → endothelial adhesion/transmigration → ROS/protease/NET-mediated necrosis. (pqac-00000001, pqac-00000002, pqac-00000003) | GO labels: neutrophil degranulation, respiratory burst, complement activation alternative pathway, Fc receptor signaling, NET formation | This pathway is best established in **pauci-immune AAV**; other necrotizing vasculitides may involve different upstream triggers. |
| Diagnostics | Diagnostic workup typically integrates **ANCA serology (MPO-ANCA/PR3-ANCA)**, urinalysis/renal function, inflammatory markers, imaging, and—when feasible—**tissue biopsy** showing necrotizing vasculitis or pauci-immune necrotizing crescentic GN. Classification may additionally use 2022 ACR/EULAR criteria for GPA/MPA/EGPA. (pqac-00000004, pqac-00000007) | Diagnostic labels: ANCA serology, kidney biopsy, chest CT, urinalysis; pathology labels: pauci-immune necrotizing crescentic glomerulonephritis | Classification criteria are for **research classification**, not identical to clinical diagnosis; ANCA-negative cases exist. |
| Biomarkers | High-yield biomarkers: **PR3-ANCA**, **MPO-ANCA**; emerging/adjunct biomarker concepts include complement activation products and urinary inflammatory markers in renal vasculitis. (pqac-00000001, pqac-00000007) | Biomarker labels: MPO-ANCA, PR3-ANCA, C5a, urinary soluble CD163 | Biomarker performance varies by organ involvement and relapse status; not all are validated for routine universal use. |
| Treatment classes | Main evidence-based treatment classes for AAV-pattern necrotizing vasculitis: **glucocorticoids**, **rituximab (anti-CD20)**, **cyclophosphamide**, maintenance agents (azathioprine, methotrexate, mycophenolate in selected settings), **avacopan (C5aR1 inhibitor)**, and **mepolizumab (anti-IL-5)** for EGPA. Plasma exchange is reserved for selected severe scenarios. (pqac-00000003, pqac-00000004, pqac-00000006) | NCIT labels if used locally: glucocorticoid therapy, rituximab, cyclophosphamide, avacopan, mepolizumab, plasma exchange | Treatment should usually be attached to the **specific subtype/organ-threatening phenotype**, not blindly to MONDO:0800113 as an umbrella term. |
| Experimental / emerging therapy | Emerging approaches include **ustekinumab** for immune-profiled ANCA glomerulonephritis, **obinutuzumab** vs rituximab in current trials, and preclinical **CD19 CAR-T** strategies reducing MPO-ANCA-driven disease in mouse models. (pqac-00000004) | Intervention labels: ustekinumab, obinutuzumab, CD19 CAR-T cell therapy | These are experimental or early-stage and should not be represented as standard of care. |
| Data model recommendation | For a knowledge base, model **necrotizing vasculitis** as an umbrella/pathology node linked to child clinical entities and to histopathology/organ-specific manifestations; attach mechanistic and treatment assertions with **subtype qualifiers** (e.g., AAV, GPA, MPA, EGPA, renal AAV). (pqac-00000000, pqac-00000005) | Use MONDO node plus linked phenotype, anatomy, cell-type, pathway, and treatment annotations; preserve provenance and subtype qualifiers | Prevents overgeneralization from AAV literature to all necrotizing vasculitis contexts. |


*Table: This table provides compact, ontology-ready annotations for necrotizing vasculitis while emphasizing that the term is best treated as a histopathologic umbrella or pattern rather than a single etiologically uniform disease. It is useful for structuring knowledge-base entries with explicit caveats about when evidence is AAV-specific versus broadly applicable.*